<code id='CB55F9FB73'></code><style id='CB55F9FB73'></style>
    • <acronym id='CB55F9FB73'></acronym>
      <center id='CB55F9FB73'><center id='CB55F9FB73'><tfoot id='CB55F9FB73'></tfoot></center><abbr id='CB55F9FB73'><dir id='CB55F9FB73'><tfoot id='CB55F9FB73'></tfoot><noframes id='CB55F9FB73'>

    • <optgroup id='CB55F9FB73'><strike id='CB55F9FB73'><sup id='CB55F9FB73'></sup></strike><code id='CB55F9FB73'></code></optgroup>
        1. <b id='CB55F9FB73'><label id='CB55F9FB73'><select id='CB55F9FB73'><dt id='CB55F9FB73'><span id='CB55F9FB73'></span></dt></select></label></b><u id='CB55F9FB73'></u>
          <i id='CB55F9FB73'><strike id='CB55F9FB73'><tt id='CB55F9FB73'><pre id='CB55F9FB73'></pre></tt></strike></i>

          focus

          focus

          author:fashion    Page View:321
          Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT
          Darron Cummings/AP

          Advisers to the Food and Drug Administration voted 11-0 on Monday to recommend the approval of a drug for early Alzheimer’s disease made by Eli Lilly — ruling that the treatment’s ability to slow the cognitive decline in patients outweighed its safety risks.

          The unanimous outcome of the daylong advisory panel was the best-case scenario for Lilly, making it likely that the FDA will approve the drug, called donanemab, for a broad population of people diagnosed with mild cognitive impairment due to Alzheimer’s. A decision is expected later this year.

          advertisement

          “The benefits outweigh the risks, as long as the risks are being monitored,” said Kathleen Poston, a neurologist at Stanford University and a member of the advisory panel.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more
          How to save health care price transparency rules
          How to save health care price transparency rules

          AdobeConsidershoppingforcerealinthegrocerystore.Buyerseasilyknowhowmanygramsofsugarandcaloriesareina

          read more
          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more

          Ebola: Gilead Sciences antiviral shows promise as new treatment

          UgandamedicalstaffatanEbolatreatmentcenterinthetownofMubende.BADRUKATUMBA/AFPviaGettyImagesAnewstudy